GlassScriptPhysician profile
Mina Lutts
NPI 1134115173
$3,192.19
in general payments reported to CMS, 2019-2025
29 companies · $97.66 in 2025
The $97.66 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $854 · 2020: $554 · 2021: $909 · 2022: $312 · 2023: $390 · 2024: $76.54 · 2025: $97.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $563.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $380.43 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $308.74 | 2019-2023 | Breztri |
| Pfizer INC. | $286.56 | 2019-2021 | |
| Abbvie INC. | $250.94 | 2021-2023 | |
| Novo Nordisk INC | $247.88 | 2019-2023 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $238.72 | 2019-2021 | |
| Allergan, INC. | $213.18 | 2019 | |
| Lilly USA, LLC | $179.81 | 2019-2023 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $136.96 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $132.85 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $103.46 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.28 | 2020-2021 | |
| Amgen INC. | $74.86 | 2019-2023 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $72.83 | 2019-2023 | Arexvy, Shingrix |
| Biohaven Pharmaceuticals, INC. | $62.59 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $60.69 | 2022-2023 | |
| Dexcom, INC. | $51.67 | 2021-2024 | Dexcom G6 Transmitter |
| Shire North American Group INC | $49.66 | 2019 | |
| Imperative Care, INC | $42.84 | 2025 | Symphony Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $38.10 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $37.12 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.58 | 2022 | |
| Exact Sciences Corporation | $19.31 | 2023 | Cologuard Collection Kit |
| Covis Pharma Gmbh | $19.29 | 2022 | |
| Renalytix Ai, INC. | $15.68 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.25 | 2019 | |
| Sanofi Pasteur INC. | $12.96 | 2019 | |
| Medicure Pharma INC. | $12.15 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mina Lutts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.